Ovarian Cysts

An ovarian cyst is a fluid-filled sac on or within the ovary. In everyday pharmacy and primary care practice, the overwhelming majority are functional cysts — a normal, physiologic byproduct of the ovulatory cycle rather than a disease process: a follicular cyst forms when the dominant follicle of the cycle fails to rupture and release an egg and instead continues to fill with fluid, while a corpus luteum cyst forms when the corpus luteum that remains after ovulation fails to regress on schedule, or bleeds internally into itself. Functional cysts are common enough that they are frequently found incidentally on pelvic ultrasound performed for an unrelated reason, and the great majority resolve spontaneously within one to three menstrual cycles without any treatment at all.^[1]

This chapter is deliberately organized around a single central tension. On one side, the two current SOGC guidelines on this topic — Guideline No. 403 on the initial investigation of adnexal masses, and Guideline No. 404 on the management of benign ovarian masses specifically — are explicit that the correct default for most patients is conservative, expectant management, and that reducing unnecessary surgery is a genuine goal of good guideline-based care here, not simply a cost consideration.^[2][1] On the other side, a genuine minority of presentations are the opposite of routine: ovarian torsion and a ruptured hemorrhagic cyst are surgical emergencies that must be recognized promptly (see Red Flags & Refer), and a small number of adnexal masses — more often, though not exclusively, in postmenopausal patients — carry genuine features of malignancy that change the entire management pathway (see Assessment & Diagnosis). Getting both halves right — treating the common, benign, self-limited presentation as exactly that, while never missing the uncommon emergency or the uncommon cancer risk — is the actual skill this chapter is trying to build.

This chapter focuses on functional cysts and provides a differential overview of the other benign adnexal masses most likely to be confused with them on ultrasound — endometrioma, mature cystic teratoma (dermoid cyst), and cystadenoma — along with the features that should raise concern for malignancy. It does not duplicate this platform's separate Ectopic Pregnancy chapter; where the two conditions overlap in presentation, this chapter cross-references that content rather than repeating it.

Hemorrhagic cyst

A hemorrhagic cyst is not a separate type of follicular structure — it is a follicular or, more often, corpus luteum cyst that has bled internally. Bleeding into a functional cyst causes genuinely acute, one-sided pelvic pain, often sudden in onset, and can be difficult to distinguish clinically from ovarian torsion or a ruptured ectopic pregnancy at first presentation (see Red Flags & Refer). On ultrasound, a hemorrhagic cyst has a distinctive complex, lacy or reticular ("fishnet" or "cobweb") internal echo pattern from fibrin strands, and may contain a retracting clot that can look worryingly like a solid mural nodule — the key distinguishing feature is that a retracting clot has no internal vascularity on colour Doppler, while a genuine solid, vascularized nodule does.^[3] Most hemorrhagic cysts resolve on their own with expectant management; the genuine emergency is a hemorrhagic cyst that ruptures with ongoing intraperitoneal bleeding, not the hemorrhagic cyst itself.

Theca lutein cysts — a rarer, hormone-driven variant

Theca lutein cysts are typically bilateral, often multicystic, and form in response to abnormally high or prolonged hCG or gonadotropin stimulation — classically gestational trophoblastic disease (molar pregnancy), multiple gestation, or ovulation-induction/assisted-reproduction cycles, including ovarian hyperstimulation syndrome. They are uncommon in routine community practice but worth recognizing by name, since they resolve as the underlying hormonal stimulus resolves and do not themselves need surgical management.

Other benign adnexal masses — a brief differential

Several other benign adnexal masses can resemble a functional cyst on ultrasound or on symptoms, and are worth naming even though full management of each is beyond this chapter's scope:

• Endometrioma ("chocolate cyst") — a cystic collection of old, degraded blood from ectopic endometrial tissue, with a classic homogeneous, low-level ("ground-glass") internal echo pattern on ultrasound. Endometriomas do not resolve spontaneously the way functional cysts do, and their presence should prompt consideration of a broader endometriosis assessment.
• Mature cystic teratoma (dermoid cyst) — a benign germ-cell tumour containing tissue from multiple germ layers (hair, sebaceous material, sometimes teeth or bone), producing a characteristically heterogeneous ultrasound appearance with a hyperechoic component and sometimes a fat-fluid level or calcification. Unlike functional cysts, dermoids do not spontaneously resolve, and their firm, often mobile, dense contents can specifically predispose to ovarian torsion.
• Cystadenoma (serous or mucinous) — a benign epithelial tumour that can grow considerably larger than a typical functional cyst and may be multiloculated on ultrasound; unlike a functional cyst it does not track with the menstrual cycle and will not resolve on interval imaging.
• Paratubal/paraovarian cyst and hydrosalpinx — arise from tissue adjacent to, rather than within, the ovary; a paratubal cyst is a simple-appearing cyst clearly separate from a normal-appearing ipsilateral ovary, and hydrosalpinx has a characteristic tubular, folded shape.

What ties this differential together clinically is that none of these entities are expected to resolve on their own the way a functional cyst is — persistence of a "simple-appearing" cyst well beyond the expected interval, or a mass that never actually looked simple in the first place, should prompt reconsideration of the diagnosis rather than repeated reassurance (see Assessment & Diagnosis and Common Errors to Avoid).

Factors associated with functional cyst formation

• Reproductive age — functional cysts require an active ovulatory cycle, so they are essentially exclusive to premenarchal-through-perimenopausal patients who are ovulating; they do not form after true menopause.
• A personal history of previous functional cysts.
• Tamoxifen therapy — a well-documented cause of enlarged, often multiloculated, functional-appearing ovarian cysts in premenopausal patients being treated for breast cancer, thought to relate to tamoxifen's partial estrogen-agonist effect on the ovary.
• Ovulation induction or controlled ovarian stimulation for fertility treatment (e.g., clomiphene citrate, gonadotropins) — a recognized cause of larger functional and theca lutein cysts, and, in more pronounced cases, of ovarian hyperstimulation syndrome.
• Early menarche.
• Cigarette smoking has been inconsistently associated with a modestly higher risk in some studies.

What lowers the risk of a future functional cyst

Ongoing use of a combined hormonal contraceptive suppresses the ovulatory cycle that gives rise to a new follicular or corpus luteum cyst in the first place, and is well established as reducing the incidence of future functional cysts.^[4] This is a genuinely different question from whether starting a combined hormonal contraceptive will treat a cyst a patient already has — it will not (see Choose Initial Treatment and Pharmacologic Treatment Options) — and the two points are commonly, and understandably, conflated by patients.

Factors that shift concern toward malignancy rather than a functional cyst

These are covered in full, with the ultrasound and laboratory framework used to act on them, in Assessment & Diagnosis; the headline risk factors are age (particularly postmenopausal status), a family history of ovarian, breast, or colorectal cancer, a known BRCA1/BRCA2 mutation or Lynch syndrome, nulliparity, and a personal history of endometriosis, which is associated with a modestly increased risk of certain ovarian cancer subtypes (clear cell and endometrioid).^[2] Multiparity, breastfeeding, and previous combined hormonal contraceptive use are each associated with a lower lifetime risk of epithelial ovarian cancer.

Distinguishing this from ectopic pregnancy — a genuinely important differential, covered elsewhere

Acute one-sided pelvic pain in a reproductive-age patient always requires a pregnancy test before anything else, because a ruptured or symptomatic ectopic pregnancy can look identical to a ruptured or torsed ovarian cyst at first presentation, and the two conditions share several of the same red-flag findings above (hemodynamic instability, peritoneal signs, referred shoulder-tip pain from intraperitoneal blood). A positive pregnancy test in this context should trigger this platform's Ectopic Pregnancy chapter — the discriminatory-zone, serial hCG, and methotrexate-eligibility framework covered there is not repeated here. A negative pregnancy test does not eliminate the need for urgent evaluation; it simply means the acute adnexal presentation is being worked up on the pathway in this chapter (torsion, hemorrhagic cyst rupture, or, less urgently, tubo-ovarian abscess) rather than the ectopic pregnancy pathway.

A prior ovarian cyst diagnosis, including one already being followed expectantly, does not make a new episode of severe acute pain "probably just the same cyst acting up" — a patient with a known cyst who develops a new, different, or more severe pain pattern needs the same emergency evaluation as anyone else, not a reflexive attribution to the known finding (see Common Errors to Avoid).

Pregnancy test first

Every reproductive-age patient being evaluated for a suspected ovarian cyst or adnexal mass needs a urine or serum pregnancy test as a first step, regardless of reported contraceptive use or last menstrual period — this rules the ectopic pregnancy pathway in or out before anything else (see Red Flags & Refer).

Transvaginal ultrasound — the primary imaging tool

Transvaginal ultrasonography is the recommended first-line imaging modality for a suspected or incidentally identified ovarian or adnexal mass; no alternative imaging modality has demonstrated sufficient superiority to justify routine use in its place.^[3] A genuinely useful practical point for scheduling a repeat or interval scan in a premenopausal patient: doing so in the early follicular (proliferative) phase of the cycle, when the ovary is normally quiescent, avoids mistaking a normal dominant follicle or a normal corpus luteum for a persistent abnormal finding.

A simple, unilocular 2 cm left ovarian cyst on transvaginal ultrasound — anechoic, thin-walled, with no septations or solid components, the classic appearance of a benign functional cyst. (James Heilman, MD, CC BY-SA 3.0, Wikimedia Commons)

Simple versus complex — the single most important ultrasound distinction

A simple cyst is unilocular, anechoic, and thin-walled (wall thickness under about 3 mm), with no septations, no solid or papillary components, and typically shows posterior acoustic enhancement — the appearance most consistent with a functional cyst, and one that is highly likely to be benign in any age group.^[3] A complex cyst has one or more additional features — septations (particularly if thick, over about 2-3 mm), a solid component, papillary projections, mixed or heterogeneous internal echoes, wall irregularity, or increased internal blood flow on colour Doppler — any of which shifts the differential away from a straightforward functional cyst and toward the other entities in Recognize the Condition, including, at the more concerning end, malignancy.

Size thresholds and follow-up intervals — and why they change with menopausal status

How large a simple cyst can be and still need no further follow-up, and how large one can be and still be reasonably managed with repeat imaging rather than surgery, both depend on menopausal status. A multidisciplinary 2019 consensus update from the Society of Radiologists in Ultrasound (SRU), aligning prior guidance with more recent large cohort data showing an exceptionally low cancer risk for simple cysts, gives the framework most consistently used in practice:^[5]

• Premenopausal: a simple cyst over 3 cm should be described in the report, but does not need follow-up imaging unless it is larger than 5-7 cm (using the higher end of that range for an exceptionally well-visualized cyst).
• Postmenopausal: the same principle applies at smaller sizes — a simple cyst over 1 cm should be described, but does not need follow-up imaging unless it is larger than 3-5 cm.

Where follow-up is warranted, an asymptomatic benign-appearing mass can generally be followed with a first repeat ultrasound at around 8-12 weeks, then yearly once it has been shown to be stable and has not developed any concerning new feature.^[3] Even simple cysts up to 10 cm in diameter, on transvaginal ultrasound performed by an experienced sonographer, are highly likely to be benign and can be safely monitored with repeat imaging rather than surgery — a finding that holds even in postmenopausal patients, and that runs counter to an older, more reflexive instinct to operate once a cyst crosses the traditional "10 cm" line.^[3] A defined upper size cutoff that mandates surgical intervention on size alone has not been firmly established; size is one input into the overall risk picture, not a rule that overrides everything else.^[3]

The IOTA Simple Rules

The International Ovarian Tumor Analysis (IOTA) group's Simple Rules use ten specific ultrasound features — five associated with benign disease ("B-features") and five associated with malignancy ("M-features") — to classify a mass as benign, malignant, or inconclusive.^[6]

A mass with one or more B-features and no M-features is classified benign; one or more M-features and no B-features is classified malignant; a mass with both B- and M-features, or with neither, is inconclusive and should be referred for assessment by an examiner experienced in gynecologic ultrasound rather than forced into either category.^[6]

O-RADS ultrasound risk stratification

The Ovarian-Adnexal Reporting and Data System (O-RADS) is a complementary, increasingly widely used ultrasound risk-stratification and structured-reporting framework from the American College of Radiology, developed by an international multidisciplinary committee that includes some of the same investigators behind current SOGC guidance on ovarian masses.^[7] O-RADS assigns a mass to one of five categories, each with an associated estimated risk of malignancy:

Whether a program uses the IOTA Simple Rules, O-RADS, or both, the underlying message is the same: an unambiguously simple cyst is a low-risk finding in any age group, while solid components, papillary projections, thick or irregular septations, ascites, and strong internal vascularity are the features that should specifically prompt escalation (see Choose Initial Treatment).

CA-125 and other serum markers

Serum CA-125 is most useful in postmenopausal patients, where its specificity and positive predictive value for malignancy are consistently higher than in premenopausal patients; a level above 35 U/mL is generally considered abnormal in this group, whereas no single evidence-based premenopausal cutoff has been established.^[3] This difference exists because CA-125 is a nonspecific marker that is also elevated by many entirely benign, common premenopausal conditions — endometriosis, uterine fibroids, pelvic inflammatory disease, and even normal pregnancy — so an elevated value in a premenopausal patient is far less specific for cancer than the same elevated value in a postmenopausal patient. Combining an elevated CA-125 with a pelvic mass in a postmenopausal patient is highly suspicious for malignancy and warrants referral to or consultation with a gynecologic oncologist.^[3]

The Risk of Malignancy Index (RMI) is a simple multimodal calculation — ultrasound score × menopausal status × serum CA-125 (U/mL) — that combines these inputs into a single number; an RMI above 200 has been reported with a pooled sensitivity of about 78% and specificity of about 87% for malignancy in a systematic review, and is one formal risk-assessment tool that can support a referral decision.^[3] Formal risk-assessment tools like the RMI, multivariate serum biomarker panels, or an IOTA-based ultrasound score are aids for judging when specialist referral is warranted — none of them are a substitute for the overall clinical picture, and no single premenopausal CA-125 threshold on its own should be treated as decisive.^[3]

If a less common ovarian histology is suspected on the basis of risk factors, symptoms, or unusual ultrasound findings — for example, a solid mass in an adolescent, raising concern for a germ-cell tumour — additional markers including beta-hCG, lactate dehydrogenase (LDH), alpha-fetoprotein, or inhibin may help refine the differential, and should be considered in that specific clinical context rather than ordered routinely for every simple cyst.^[3]

Investigations

• Urine or serum pregnancy test in every reproductive-age patient.
• Transvaginal ultrasound (add transabdominal imaging if the mass extends beyond the pelvis, or in a young/virginal patient, where transabdominal imaging is more appropriate).
• Serum CA-125 — most useful and most often indicated in postmenopausal patients or when ultrasound findings are not clearly simple; not routinely needed for a classic simple cyst in a premenopausal patient.
• Complete blood count if there is bleeding, suspected rupture, or diagnostic uncertainty about acute blood loss.
• Additional tumour markers (beta-hCG, LDH, alpha-fetoprotein, inhibin) only if a less common histology is specifically suspected, per the discussion above.

• Rule out the two genuine emergencies — ectopic pregnancy and ovarian torsion/hemorrhagic rupture — before anything else in a patient with acute pain (see Red Flags & Refer).
• Correctly characterize a cyst as simple or complex on ultrasound, and apply a recognized risk-stratification framework (IOTA Simple Rules or O-RADS) when it is not obviously simple, to decide who genuinely needs specialist referral (see Assessment & Diagnosis).
• Default to expectant management with interval ultrasound for an asymptomatic, premenopausal patient with a small simple cyst — the correct, evidence-based first step for the great majority of patients, not a fallback for lack of a better option.
• Provide effective analgesia for a symptomatic but benign-appearing simple cyst without escalating to surgery on symptoms alone.
• Counsel accurately on combined hormonal contraceptives: genuinely effective at preventing future functional cysts, genuinely ineffective at treating the current one.
• Apply a lower threshold for concern and specialist involvement in postmenopausal patients, reflecting their different baseline probability of malignancy for the same ultrasound finding.
• Avoid both of the errors that make this condition genuinely tricky to manage well: over-medicalizing a self-limited, benign, expected finding, and under-recognizing the uncommon but genuinely dangerous or malignant presentation.

• Set expectations honestly at diagnosis: most functional cysts resolve within one to three menstrual cycles without any treatment, and the plan for a genuinely simple cyst is monitoring, not medication.
• Schedule interval ultrasound, where indicated, in the early follicular (proliferative) phase for a premenopausal patient, to avoid confusing a normal dominant follicle or corpus luteum with a persistent finding (see Assessment & Diagnosis).
• For a patient with a known, larger cyst, some clinicians advise avoiding particularly vigorous or high-impact activity until the cyst has resolved or been reassessed, given a theoretical association between vigorous activity and torsion or rupture — the evidence for this specific advice is limited, and it should be offered as a reasonable precaution rather than a source of significant alarm or activity restriction for a small, low-risk cyst.
• Heat (a heating pad or warm bath) is a reasonable, low-risk adjunct for cyclic pelvic discomfort alongside analgesia.
• Explicitly acknowledge that watchful waiting can be genuinely anxiety-provoking for a patient who has just been told she has a "cyst" — plain-language reassurance about how common and how frequently self-limited functional cysts are is a real part of good care here, not a formality.
• For a patient proceeding to surgery, defer specific pre- and post-operative instructions to the surgical team, but reinforce that ovarian-sparing surgery is the norm for a presumed benign mass, and confirm the patient understands what was actually removed (cyst only, versus the ovary itself) at follow-up.

Pregnancy

A corpus luteum cyst is the expected physiologic finding of early pregnancy and does not, on its own, need investigation beyond routine dating ultrasound (see Recognize the Condition). More broadly, most adnexal masses identified in pregnancy carry a low risk of malignancy or acute complication and can be managed expectantly; across several cohorts, 51-92% of adnexal masses in pregnancy resolved on their own, and malignancy was diagnosed in only 1.2-6.8% of masses that persisted.^[3] The most commonly reported pathologic diagnoses in pregnancy are mature teratomas and paraovarian or corpus luteum cysts.^[3] If additional imaging beyond transvaginal (and, depending on gestational age, transabdominal) ultrasound is needed, MRI is the modality of choice in pregnancy, since it images deep soft-tissue structures without operator dependence and does not use ionizing radiation.^[3] If surgical intervention is genuinely warranted for symptoms or suspected malignancy, both laparoscopic and open approaches have data supporting their relative safety, with laparoscopic management most established in the second trimester specifically.^[3] For analgesia in a pregnant patient with a symptomatic simple cyst, acetaminophen is generally preferred over an NSAID, particularly from around 20 weeks' gestation onward, given fetal renal and ductus arteriosus concerns with prolonged or late-pregnancy NSAID exposure (see Pharmacologic Treatment Options).

Postmenopausal patients

Consultation with or referral to a gynecologic oncologist is appropriate for a postmenopausal patient with an elevated CA-125 together with ultrasound findings suggestive of malignancy, ascites, a nodular or fixed pelvic mass, or evidence of abdominal or distant metastasis; the same applies to a premenopausal patient with a very elevated CA-125 and the same concerning findings, and to any patient — pre- or postmenopausal — with an elevated score on a formal risk-assessment tool such as the RMI, a multivariate serum biomarker panel, or an IOTA-based ultrasound scoring system.^[3] Independent of any of these imaging or biomarker findings, referral to a gynecologic oncologist is also appropriate for a patient with a personal or family history of a hereditary cancer-susceptibility syndrome (such as a BRCA1/BRCA2 mutation or Lynch syndrome), and for a patient with a personal history of infertility or endometriosis.^[2]

Adolescents

Evaluation of an adnexal mass in an adolescent broadly mirrors the premenopausal approach, but transabdominal rather than transvaginal ultrasound is generally preferred for a young, virginal, or prepubertal patient.^[3] Ovarian conservation to preserve fertility should be prioritized specifically in this age group, and germ-cell tumours — rare overall but the most common ovarian malignancy in children and adolescents — are the reason additional tumour markers (beta-hCG, alpha-fetoprotein, LDH) are considered more readily for a solid or unusual-appearing mass in this population than in an adult with a classic simple cyst.^[3]

Tamoxifen and subdermal contraceptive implant users — an expected, transient finding

A functional-appearing ovarian cyst found on routine surveillance imaging in a patient taking tamoxifen, or on incidental imaging in a patient using an etonogestrel subdermal contraceptive implant, does not automatically need oncology referral simply because of the medication — apply the same simple-versus-complex framework as any other patient (see Assessment & Diagnosis). Ovarian cysts or enlarged follicles are a genuinely common and expected finding during the first year of etonogestrel implant use specifically, rising from about 5.2% of users at 3 months to 26.7% at 12 months, and are transient — this is not a reason to remove or discontinue an otherwise well-tolerated implant.^[8]

Future fertility

When surgery is genuinely needed, ovarian-sparing cystectomy rather than oophorectomy should be prioritized in any patient who has not completed childbearing, including adolescents and premenopausal adults — this is a recurring theme across this chapter's guidance, not a special exception (see Choose Initial Treatment).^[3]

Interval imaging

Where follow-up is indicated (see Assessment & Diagnosis), an asymptomatic benign-appearing mass is generally followed with a first repeat transvaginal ultrasound at around 8-12 weeks — timed, in a premenopausal patient, to the early follicular phase where practical — then yearly once the mass has been shown to be stable and free of any new concerning feature.^[3] A cyst that has genuinely resolved needs no further imaging; a stable, unambiguously simple cyst does not need indefinite ongoing surveillance once it has demonstrated real stability, since the potential harms of unnecessary continued monitoring — patient anxiety, cost, incidental findings requiring their own work-up — can outweigh the benefit at that point.^[3]

What should change the plan mid-monitoring

A cyst that enlarges rather than shrinks on interval imaging, or that develops a new complex feature (a septation, solid component, papillary projection, or increased internal vascularity) that was not present initially, is no longer simply being "watched" — it is a new risk-stratification problem and should be run back through the IOTA/O-RADS and CA-125/RMI framework in Assessment & Diagnosis rather than continuing on the original follow-up schedule.

Postmenopausal patients

Apply the same interval-imaging principles at the lower postmenopausal size threshold (see Assessment & Diagnosis), and keep a lower overall threshold to move from observation to referral if CA-125 becomes elevated or a complex feature appears on any follow-up scan (see Special Populations).

Safety-netting at every visit

Repeat the red-flag warning signs (sudden severe pain, hemodynamic instability, peritoneal signs, fever) at every visit for a patient being followed expectantly, regardless of how many prior visits have been reassuring — this is not a one-time conversation at diagnosis (see Red Flags & Refer).

1. A "simple" cyst has not resolved by the expected follow-up interval: reconsider the diagnosis — this may not be a functional cyst at all (see Recognize the Condition) — and re-run the mass through the IOTA/O-RADS framework and, where appropriate, CA-125/RMI rather than simply extending the observation period again.
2. The cyst enlarges on interval imaging rather than shrinking or resolving: treat this the same way — reassess characterization and consider referral rather than continuing the same monitoring schedule.
3. A new complex feature appears on follow-up imaging that was not present initially (a septation, solid component, papillary projection, or increased vascularity): this is a materially different clinical picture, not a continuation of watchful waiting for the original finding.
4. Persistent significant pain despite an adequate analgesic trial in a cyst that remains genuinely simple on imaging: reassess for an alternative cause of the pain, and consider surgical consultation for symptom control — ongoing pain alone, not imaging findings, can be a valid reason for surgery in this situation.
5. A patient started on a combined hormonal contraceptive for future prevention develops a new functional cyst anyway: this is not, on its own, evidence that the contraceptive "doesn't work" for this purpose — reassess adherence and correct use before concluding the strategy has failed.
6. Any new red-flag symptom during expectant management — sudden severe pain, hemodynamic instability, peritoneal signs, or fever: refer emergently per Red Flags & Refer regardless of where the patient is in the monitoring interval, not as a deviation from the plan but as the plan working correctly.

• Assuming a combined hormonal contraceptive will make an existing cyst go away faster — trial evidence shows it does not; its genuine role is preventing future cysts, not treating the current one.
• Reflexively referring or scheduling surgery for a small, clearly simple cyst in a premenopausal patient — this is over-treatment of an evidence-based default that should instead be managed expectantly.
• Applying the same size threshold and follow-up pattern to postmenopausal patients as premenopausal ones, without adjusting for the lower threshold that genuinely applies after menopause.
• Attributing a new, different, or more severe pain pattern to "the cyst we already know about" without reassessing for torsion or rupture.
• Treating an intermittent or waxing-and-waning pain pattern as reassuring against torsion — partial or intermittent torsion can present exactly this way.
• Ordering CA-125 reflexively in a premenopausal patient and treating a mildly elevated result as diagnostic of cancer — many entirely benign, common premenopausal conditions elevate CA-125.
• Forgetting the pregnancy test in a reproductive-age patient with pelvic pain, regardless of reported contraceptive use.
• Mistaking a retracting clot within a hemorrhagic cyst for a solid, vascularized, malignant-appearing nodule — check for internal vascularity on Doppler before assuming the worst.
• Continuing indefinite serial monitoring of a mass that has already demonstrated genuine stability over an appropriate interval — the potential harms of unnecessary ongoing imaging and patient anxiety can outweigh the benefit at that point.
• Missing the referral triggers that apply regardless of ultrasound or biomarker findings — a personal or family history of a hereditary cancer-susceptibility syndrome, or a personal history of infertility or endometriosis, warrants gynecologic oncology referral even when imaging looks reassuring.

How to use this table: doses are adult doses for ovarian cyst management specifically and require patient-specific confirmation (renal/hepatic function, pregnancy status, allergy history). Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Analgesia for a Symptomatic Simple Cyst

None of these medications change how quickly a cyst resolves — they treat pain only, while the cyst itself is followed expectantly (see Choose Initial Treatment).^[3]

Contraception — Prevention of Future Functional Cysts, Not Treatment of an Existing Cyst

Randomized trial evidence consistently shows starting a combined hormonal contraceptive does not hasten resolution of a cyst a patient already has; its genuine, evidence-supported role is suppressing ovulation to reduce the chance of a future functional cyst.^[4]

Progestin-only methods suppress ovulation less consistently than combined hormonal contraceptives (with the exception of higher-dose injectable medroxyprogesterone acetate), so they are not a reliable choice specifically for preventing future functional cysts. A functional-appearing cyst found incidentally in a patient using the etonogestrel subdermal implant is a genuinely common, expected, and transient finding — not a reason to remove the implant (see Special Populations).^[8]

When to refer to a gynecologic oncologist — regardless of what management step the patient is otherwise on

Evidence note: drug inventory, dosing, and referral criteria reflect current SOGC guidance on adnexal and benign ovarian masses, cross-checked against ACOG's more granular ultrasound, CA-125, and RMI detail, and the primary IOTA and Cochrane evidence each is based on.^[2][1][3]